Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Ipsen Promesses News

    112,90 € +0,09% +0,10 €
    09:44:20 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0ESMG
    ISIN: FR0010259150
    US-Symbol: IPSEF
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 7,28
    MD5VXB

    Ad-hocs

    24.04.24 - GlobeNewswire
    Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
    PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​care biopharmaceutical company, today presents its sales for the first quarter of 2024.
    22.04.24 - GlobeNewswire
    Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
    Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will ...
    02.04.24 - GlobeNewswire
    Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
    Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-​drug conjugate, completing the final stages of pre-​clinical development ...
    13.02.24 - GlobeNewswire
    Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
    Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde ® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements ...
    08.02.24 - GlobeNewswire
    Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
    Total-​sales growth in FY 2023 of 6.7% at CER 1 (3.4% as reported) included strong sales from the growth platforms 2 and good contributions from the new medicines. A core ...
    22.01.24 - GlobeNewswire
    Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
    Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-​free survival benefit for combination of Cabometyx ® and atezolizumab in ...
    07.12.23 - GlobeNewswire
    Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
    New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application ...
    07.12.23 - GlobeNewswire
    Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
    PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.
    13.11.23 - GlobeNewswire
    Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
    ELATIVE ® Phase III trial confirms potential for investigational elafibranor as a novel, first-​in-class, dual PPAR α,δ agonist for patients with primary biliary cholangitis. Elafibranor ...
    26.10.23 - GlobeNewswire
    Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
    Paris (France), 26 October 2023
    23.10.23 - GlobeNewswire
    Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
    Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay ® (odevixibat) based on Phase III ASSERT clinical-​trial data in Alagille ...
    03.10.23 - GlobeNewswire
    Ipsen updates on QM-1114 regulatory process
    PARIS, FRANCE, 3 October 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its partner Galderma has confirmed receipt from the FDA of a Complete Response Letter ...
    04.09.23 - GlobeNewswire
    Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
    PARIS, FRANCE, 4 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-​optation of Pascal Touchon to its Board as an independent director, effective 4 ...
    01.09.23 - GlobeNewswire
    Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
    PARIS, FRANCE, 1 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​driven biopharmaceutical company, announced today the appointment of Christelle ...
    21.08.23 - GlobeNewswire
    Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
    – Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel ...
    16.08.23 - GlobeNewswire
    US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
    Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-​rare bone disease, fibrodysplasia ossificans progressiva ...
    27.07.23 - GlobeNewswire
    Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
    Paris , France : 27 July 202 3 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​care biopharmaceutical company, presents today its financial results for the first half of 2023.
    24.07.23 - GlobeNewswire
    Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023
    PARIS, FRANCE, 24 July 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) announced today that the Board of Directors of Ipsen has been informed of certain changes of the shareholders’ ...
    21.07.23 - GlobeNewswire
    Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome  
    Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-​trial data in Alagille syndrome (ALGS) Negative opinion ...
    19.07.23 - GlobeNewswire
    Ipsen announces European Commission decision on palovarotene for the treatment of FOP
    European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva (FOP) Decision follows negative opinion ...

    Newssuche

    Videos

    newspaper
    09:30 Uhr +21,14%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »